Your browser doesn't support javascript.
loading
Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data.
Munté, Elisabet; Feliubadaló, Lídia; Del Valle, Jesús; González, Sara; Ramos-Muntada, Mireia; Balmaña, Judith; Ramon Y Cajal, Teresa; Tuset, Noemí; Llort, Gemma; Cadiñanos, Juan; Brunet, Joan; Capellá, Gabriel; Lázaro, Conxi; Pineda, Marta.
Affiliation
  • Munté E; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain.
  • Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud C
  • Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud C
  • González S; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain.
  • Ramos-Muntada M; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud Carlos III, Madrid, Spain.
  • Balmaña J; High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Medical Oncology Department, University Hospital of Vall d'Hebron, Barcelona, Spain.
  • Ramon Y Cajal T; Familial Cancer Clinic, Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain.
  • Tuset N; Medical Oncology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Llort G; Department of Medical Oncology Parc Taulí, Hospital Universitari Parc Taulí Sabadell, Barcelona, Spain.
  • Cadiñanos J; R&D Laboratory, Fundación Centro Médico de Asturias-IMOMA, Oviedo, Spain.
  • Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud Carlos III, Madrid, Spain; Precision Oncology Group (OncoGir_Pro), Institut d'Investigació Biomèdica de Girona, Girona, Spain.
  • Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud C
  • Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud C
  • Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain; Ciber Oncología, Instituto Salud C
J Mol Diagn ; 26(8): 727-738, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38851388
ABSTRACT
The molecular diagnosis of mismatch repair-deficient cancer syndromes is hampered by difficulties in sequencing the PMS2 gene, mainly owing to the PMS2CL pseudogene. Next-generation sequencing short reads cannot be mapped unambiguously by standard pipelines, compromising variant calling accuracy. This study aimed to provide a refined bioinformatic pipeline for PMS2 mutational analysis and explore PMS2 germline pathogenic variant prevalence in an unselected hereditary cancer (HC) cohort. PMS2 mutational analysis was optimized using two cohorts 192 unselected HC patients for assessing the allelic ratio of paralogous sequence variants, and 13 samples enriched with PMS2 (likely) pathogenic variants screened previously by long-range genomic DNA PCR amplification. Reads were forced to align with the PMS2 reference sequence, except those corresponding to exon 11, where only those intersecting gene-specific invariant positions were considered. Afterward, the refined pipeline's accuracy was validated in a cohort of 40 patients and used to screen 5619 HC patients. Compared with our routine diagnostic pipeline, the PMS2_vaR pipeline showed increased technical sensitivity (0.853 to 0.956, respectively) in the validation cohort, identifying all previously PMS2 pathogenic variants found by long-range genomic DNA PCR amplification. Fifteen HC cohort samples carried a pathogenic PMS2 variant (15 of 5619; 0.285%), doubling the estimated prevalence in the general population. The refined open-source approach improved PMS2 mutational analysis accuracy, allowing its inclusion in the routine next-generation sequencing pipeline streamlining PMS2 screening.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Testing / Computational Biology / High-Throughput Nucleotide Sequencing / Mismatch Repair Endonuclease PMS2 Limits: Humans Language: En Journal: J Mol Diagn Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Testing / Computational Biology / High-Throughput Nucleotide Sequencing / Mismatch Repair Endonuclease PMS2 Limits: Humans Language: En Journal: J Mol Diagn Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: